医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2013年
2期
107-108
,共2页
内窥镜逆行胰胆管造影术%胰腺炎%高淀粉酶血症%硝酸甘油%吲哚美辛
內窺鏡逆行胰膽管造影術%胰腺炎%高澱粉酶血癥%硝痠甘油%吲哚美辛
내규경역행이담관조영술%이선염%고정분매혈증%초산감유%신타미신
Endoscopic retrograde cholangiopancreatography%Pancreatitis%Hyperamylasemia%Nitroglycerin%Indomethacin
目的:观察并比较硝酸甘油与吲哚美辛预防经内镜逆行胰胆管造影(ERCP)术后胰腺炎及高淀粉酶血症的临床效果.方法:将2010年2月至2012年9月间本院消化内科收治的210例接受ERCP诊治患者随机分为三组:硝酸甘油组术前5 min给予硝酸甘油片0.5mg舌下含服、术后以硝酸甘油针剂15μg/(kg?min),静脉维持6 h;吲哚美辛组术前30 min给予吲哚美辛栓剂100 mg直肠给药;对照组不予任何预防药物.检测所有患者术前、术后24 h血清淀粉酶水平,比较三组患者ERCP术后胰腺炎和高淀粉酶血症发生率,观察不良反应.结果:三组患者ERCP术前血清淀粉酶均为正常值.硝酸甘油组与吲哚美辛组ERCP术后胰腺炎发生率分别为10.61%、11.94%,无显著差异(p>0.05),但均明显低于对照组(25.71%),差异有统计学意义(p<0.05).硝酸甘油组与吲哚美辛组ERCP术后高淀粉酶血症发生率分别为36.36%、35.82%,无显著差异(p>0.05),但均明显低于对照组(61.43%),差异有统计学意义(p<0.05).硝酸甘油组与吲哚美辛组均未出现严重不良反应.结论: ERCP术前预防性应用硝酸甘油与吲哚美辛都可有效降低术后胰腺炎和高淀粉酶血症的发生率,且安全性好.
目的:觀察併比較硝痠甘油與吲哚美辛預防經內鏡逆行胰膽管造影(ERCP)術後胰腺炎及高澱粉酶血癥的臨床效果.方法:將2010年2月至2012年9月間本院消化內科收治的210例接受ERCP診治患者隨機分為三組:硝痠甘油組術前5 min給予硝痠甘油片0.5mg舌下含服、術後以硝痠甘油針劑15μg/(kg?min),靜脈維持6 h;吲哚美辛組術前30 min給予吲哚美辛栓劑100 mg直腸給藥;對照組不予任何預防藥物.檢測所有患者術前、術後24 h血清澱粉酶水平,比較三組患者ERCP術後胰腺炎和高澱粉酶血癥髮生率,觀察不良反應.結果:三組患者ERCP術前血清澱粉酶均為正常值.硝痠甘油組與吲哚美辛組ERCP術後胰腺炎髮生率分彆為10.61%、11.94%,無顯著差異(p>0.05),但均明顯低于對照組(25.71%),差異有統計學意義(p<0.05).硝痠甘油組與吲哚美辛組ERCP術後高澱粉酶血癥髮生率分彆為36.36%、35.82%,無顯著差異(p>0.05),但均明顯低于對照組(61.43%),差異有統計學意義(p<0.05).硝痠甘油組與吲哚美辛組均未齣現嚴重不良反應.結論: ERCP術前預防性應用硝痠甘油與吲哚美辛都可有效降低術後胰腺炎和高澱粉酶血癥的髮生率,且安全性好.
목적:관찰병비교초산감유여신타미신예방경내경역행이담관조영(ERCP)술후이선염급고정분매혈증적림상효과.방법:장2010년2월지2012년9월간본원소화내과수치적210례접수ERCP진치환자수궤분위삼조:초산감유조술전5 min급여초산감유편0.5mg설하함복、술후이초산감유침제15μg/(kg?min),정맥유지6 h;신타미신조술전30 min급여신타미신전제100 mg직장급약;대조조불여임하예방약물.검측소유환자술전、술후24 h혈청정분매수평,비교삼조환자ERCP술후이선염화고정분매혈증발생솔,관찰불량반응.결과:삼조환자ERCP술전혈청정분매균위정상치.초산감유조여신타미신조ERCP술후이선염발생솔분별위10.61%、11.94%,무현저차이(p>0.05),단균명현저우대조조(25.71%),차이유통계학의의(p<0.05).초산감유조여신타미신조ERCP술후고정분매혈증발생솔분별위36.36%、35.82%,무현저차이(p>0.05),단균명현저우대조조(61.43%),차이유통계학의의(p<0.05).초산감유조여신타미신조균미출현엄중불량반응.결론: ERCP술전예방성응용초산감유여신타미신도가유효강저술후이선염화고정분매혈증적발생솔,차안전성호.
Objective To compare the preventive effect of nitroglycerin and indomethacin on post-ERCP pancreatitis (PEP) and hyperamylasemia. Methods A total of 210 patients were enroled to receive endoscopic retrograde cholangiopancreatograph(ERCP). Al patients were divided into three groups: nitroglycerin group (buccal nitroglycerin plus intravenous nitroglycerin) or indomethacin group (anal indomethacin) or control group (no special medication). Incidence of PEP and hyperamylasemia were observed and compared between the three groups. Results The incidences of PEP and hyperamylasemia in both nitroglycerin group and indomethacin group were significantly lower than those in control group(p<0.05), while there was no significant difference between nitroglycerin group and indomethacin group (p>0.05). No severe adverse effects were observed. Conclusion Both nitroglycerin and indomethacin can safely effectively prevent post-ERCP pancreatitis and hyperamylaemia.
